MX2017012783A - Carbamatos de alquinilo sustituidos por xantina/carbamatos inversos como antagonistas de a2b. - Google Patents

Carbamatos de alquinilo sustituidos por xantina/carbamatos inversos como antagonistas de a2b.

Info

Publication number
MX2017012783A
MX2017012783A MX2017012783A MX2017012783A MX2017012783A MX 2017012783 A MX2017012783 A MX 2017012783A MX 2017012783 A MX2017012783 A MX 2017012783A MX 2017012783 A MX2017012783 A MX 2017012783A MX 2017012783 A MX2017012783 A MX 2017012783A
Authority
MX
Mexico
Prior art keywords
carbamates
xanthine
substituted alkynyl
reverse
antagonists
Prior art date
Application number
MX2017012783A
Other languages
English (en)
Inventor
Thompson Robert
Beauglehole Anthony
Wang Guoquan
Original Assignee
Lewis And Clark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lewis And Clark Pharmaceuticals Inc filed Critical Lewis And Clark Pharmaceuticals Inc
Publication of MX2017012783A publication Critical patent/MX2017012783A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona carbamatos de alquinilo sustituidos con xantina/carbamatos inversos y sus derivados y composiciones farmacéuticas que contienen los mismos que son antagonistas selectivos de receptores A2B de adenosina (AR). Estos compuestos y composiciones son útiles como agentes farmacéuticos.
MX2017012783A 2015-04-08 2016-04-08 Carbamatos de alquinilo sustituidos por xantina/carbamatos inversos como antagonistas de a2b. MX2017012783A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562144371P 2015-04-08 2015-04-08
PCT/US2016/026807 WO2016164838A1 (en) 2015-04-08 2016-04-08 Xanthine-substituted alkynyl carbamates/reverse carbamates as a2b antagonists

Publications (1)

Publication Number Publication Date
MX2017012783A true MX2017012783A (es) 2018-01-30

Family

ID=57072855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012783A MX2017012783A (es) 2015-04-08 2016-04-08 Carbamatos de alquinilo sustituidos por xantina/carbamatos inversos como antagonistas de a2b.

Country Status (16)

Country Link
US (1) US9593118B2 (es)
EP (1) EP3280417B1 (es)
JP (1) JP6738405B2 (es)
KR (1) KR20170133493A (es)
CN (1) CN107530349B (es)
AU (1) AU2016246068B2 (es)
BR (1) BR112017021386A2 (es)
DK (1) DK3280417T3 (es)
EA (1) EA036954B1 (es)
ES (1) ES2828574T3 (es)
IL (1) IL254902B (es)
MX (1) MX2017012783A (es)
PL (1) PL3280417T3 (es)
PT (1) PT3280417T (es)
SG (1) SG11201707753XA (es)
WO (1) WO2016164838A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3090922A1 (en) 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
CN112592354B (zh) 2019-07-30 2022-05-27 厦门宝太生物科技股份有限公司 一种异噁唑并嘧啶类杂环化合物的制备方法
CN112479956A (zh) * 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法
EP4126866A1 (en) * 2020-03-26 2023-02-08 Inspyr Therapeutics, Inc. 8-substituted diaryl xanthines as dual a2a-a2b antagonists
JPWO2022050230A1 (es) * 2020-09-03 2022-03-10

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558051A (en) 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
US6187780B1 (en) 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
US7253176B1 (en) 2000-05-04 2007-08-07 K.U. Leuven Research & Development Immunosuppressive effects of 8-substituted xanthine derivatives
WO2006091896A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyridyl substituted xanthines
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
WO2011005871A1 (en) * 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
NZ711718A (en) * 2013-03-15 2020-05-29 Hydra Biosciences Llc Substituted xanthines and methods of use thereof

Also Published As

Publication number Publication date
WO2016164838A1 (en) 2016-10-13
EP3280417A1 (en) 2018-02-14
CN107530349B (zh) 2021-01-08
ES2828574T3 (es) 2021-05-26
EP3280417B1 (en) 2020-07-29
JP2018510918A (ja) 2018-04-19
PL3280417T3 (pl) 2020-12-28
KR20170133493A (ko) 2017-12-05
CN107530349A (zh) 2018-01-02
AU2016246068A1 (en) 2017-11-16
US20160297819A1 (en) 2016-10-13
US9593118B2 (en) 2017-03-14
DK3280417T3 (da) 2020-11-02
EP3280417A4 (en) 2019-01-23
IL254902B (en) 2021-05-31
EA036954B1 (ru) 2021-01-19
SG11201707753XA (en) 2017-10-30
PT3280417T (pt) 2020-10-30
IL254902A0 (en) 2017-12-31
EA201792156A1 (ru) 2018-09-28
JP6738405B2 (ja) 2020-08-12
AU2016246068B2 (en) 2020-08-27
BR112017021386A2 (pt) 2018-07-03

Similar Documents

Publication Publication Date Title
MX2017012783A (es) Carbamatos de alquinilo sustituidos por xantina/carbamatos inversos como antagonistas de a2b.
KR102281667B9 (ko) 아트로핀 약학 조성물 (atropine pharmaceutical compositions)
IL272056A (en) Heterocyclic compounds as adenosine antagonists
SG11201706050WA (en) Substituted nucleoside derivatives useful as anticancer agents
SG10201912578SA (en) Base stocks and lubricant compositions containing same
NZ703992A (en) N-alkyl 2-(disubstituted)alkynyladenosine-5’-uronamides as a2a agonists
SG11202001340VA (en) Quinoxaline derivatives as adenosine receptor antagonists
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
IL260720B (en) Orexin-1 receptor inhibitors and preparations containing them
GB201819957D0 (en) Novel quinazolinone derivatives inhibiting piek and pharmaceutical composition containing same
MD3347360T2 (ro) Compuși utili pentru inhibarea ROR-gama-t
GB201705303D0 (en) Pharmaceutical compositions
GB201713660D0 (en) Pharmaceutical compositions
IL304109A (en) Pharmaceutical preparations containing spinamide
WO2019054891A3 (en) Trpv2 antagonists
SG11202000823WA (en) Thiazolopyridine derivatives as adenosine receptor antagonists
GB201705305D0 (en) Pharmaceutical compositions
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
GB201705304D0 (en) Pharmaceutical compositions
GB201705306D0 (en) Pharmaceutical compositions
ZA201901002B (en) Anti-retroviral compositions
IL259900A (en) Aminoazole derivatives, compositions containing same and uses thereof
ZA202003079B (en) Pharmaceutical compositions comprising safinamide
PL3558261T3 (pl) Kompozycje farmaceutyczne zawierające safinamid
GB201710114D0 (en) Pharmaceutical compositions